Silexion Therapeutics (SLXN) Free Cash Flow (2023 - 2026)

Silexion Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 48.27% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$12.0 million (down 31.76% YoY), while the FY2025 annual figure was -$10.8 million, down 28.63% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$3.6 million, down from -$3.0 million in the prior quarter.
• The five-year high for Free Cash Flow was -$691000.0 in Q3 2023, with the low at -$3.6 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$2.5 million (2025), against an average of -$2.2 million.
• Peak annual rise in Free Cash Flow reached 36.53% in 2024, while the deepest fall reached 286.25% in 2024.
• Silexion Therapeutics' Free Cash Flow stood at -$1.3 million in 2023, then sank by 132.04% to -$2.9 million in 2024, then decreased by 3.14% to -$3.0 million in 2025, then slipped by 20.81% to -$3.6 million in 2026.
• Business Quant data shows SLXN's Free Cash Flow at -$3.6 million in Q1 2026, -$3.0 million in Q4 2025, and -$2.8 million in Q3 2025.